Выбор редакции

Acadia Healthcare (ACHC) Q3 Earnings, Revenues Lag Estimates

Acadia Healthcare Company Inc. ACHC reported third-quarter 2017 adjusted earnings of 58 cents per share, missing the Zacks Consensus Estimate by 10.8%. Moreover, earnings remained flat year over year.

During the reported quarter, the company witnessed better performance with respect to its U.S. operations, despite the substantial impact from the unprecedented hurricane activity, which lowered the quarter’s earnings by 2 cents per diluted share.

The results of the third quarter were primarily affected by the divestiture of 22 facilities in the U.K. as of Nov 30, 2016.

Quarter Details

Acadia Healthcare’s revenues for the third quarter declined 2.4% to $716.7 million from the prior-year quarter, missing the Zacks Consensus Estimate by 1.5%. The decline could be attributed to higher provision for doubtful accounts.

Same facility revenues increased 5.5%, with a 3.5% increase in patient days and a 1.9% increase in revenue per patient day.

The same facility revenue growth can be attributed to the addition of more than 600 new beds to existing facilities in the 12 months ended Sep 30, 2017. To existing facilities, 179 new beds were added. The company anticipates to add 800 new beds to existing facilities and de novo facilities in 2017.

U.S. same facility revenues were up 6.3% from the year-ago quarter. The company also recorded a 4.2% increase in patient days from 2016.

U.K. same facility revenues inched up 3.8% year over year to $236.4 million. The number of patient days rose 2.5% from the year-ago quarter.

We note that revenues per patient day were up approximately 2% in the United States and rose 1.3% in the U.K.

Total expenses declined nearly 23% year over year to $655.3 million due to lower salaries, wages and benefits, supplies, interest expenses, as well as rents and leases.

Financial Update

Cash and cash equivalents as of Sep 30, 2017 were $75.7 million, up 32.6% from year-end 2016.

Long-term debt was $3.2 billion as of Sep 30, 2017, down 0.6% from the 2016-end level.

Net cash provided by operating activities for the nine months ended Sep 30, 2017 was $271.3 million, up 4.5%, compared to the same period in 2016.

2017 Guidance

The company expects adjusted earnings per diluted share between $2.23 and $2.25 on revenues of $2.82-$2.83 billion.

Adjusted EBITDA is expected between $600 million and $605 million.

The company expects an exchange rate of $1.28 per British Pound Sterling and a tax rate of about 25%.

Zacks Rank

Acadia Healthcare currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other Companies from the Medical Sector

Among the other firms in the medical sector that have reported their third-quarter earnings so far, the bottom line of Centene Corp. CNC, Quest Diagnostics Incorporated DGX and UnitedHealth Group Inc. UNH beat their respective Zacks Consensus Estimate.

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.

Click here for Zacks' secret trade>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research